QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.107.020115v1 36/7/1291    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bui, P. H. Articles by Hankinson, O. Search for Related Content PubMed PubMed Citation Articles by Bui, P. H. Articles by Hankinson, O.

The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than Mibefradil

Molecular Toxicology Interdepartmental Program (P.H.B., O.H.), Department of Pathology and Laboratory Medicine (P.H.B., O.H.), Jonsson Comprehensive Cancer Center (P.H.B., O.H.), and Department of Neurobiology (A.Q.), University of California, Los Angeles, Los Angeles, California; and Neurology and Research Services, Veterans Affairs Greater Los Angeles, Los Angeles, California (A.Q., A.H.)

(Received December 20, 2007; Accepted April 8, 2008)

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
A novel mibefradil derivative, NNC55-0396, designed to be hydrolysis-resistant, was shown to be a selective T-type Ca²⁺ channel inhibitor without L-type Ca²⁺ channel efficacy. However, its effects on cytochromes P450 (P450s) have not previously been examined. We investigated the inhibitory effects of NNC55-0396 toward seven major recombinant human P450s—CYP3A4, CYP2D6, CYP1A2, CYP2C9, CYP2C8, CYPC19, and CYP2E1—and compared its effects with those of mibefradil and its hydrolyzed metabolite, Ro40-5966. Our results show that CYP3A4 and CYP2D6 are the two P450s most affected by mibefradil, Ro40-5966, and NNC55-0396. Mibefradil (IC₅₀ = 33 ± 3 nM, K_i = 23 ± 0.5 nM) and Ro40-5966 (IC₅₀ = 30 ± 7.8 nM, K_i = 21 ± 2.8 nM) have a 9- to 10-fold greater inhibitory activity toward recombinant CYP3A4 benzyloxy-4-trifluoromethylcoumarin-O-debenzylation activity than NNC55-0396 (IC₅₀ = 300 ± 30 nM, K_i = 210 ± 6 nM). More dramatically, mibefradil (IC₅₀ = 566 ± 71 nM, K_i = 202 ± 39 nM) shows 19-fold higher inhibition of CYP3A-associated testosterone 6β-hydroxylase activity in human liver microsomes compared with NNC55-0396 (IC₅₀ = 11 ± 1.1 µM, K_i = 3.9 ± 0.4 µM). Loss of testosterone 6β-hydroxylase activity by recombinant CYP3A4 was shown to be time- and concentration-dependent with both compounds. However, NNC55-0396 (K_I = 3.87 µM, K_inact = 0.061/min) is a much less potent mechanism-based inhibitor than mibefradil (K_I = 83 nM, K_inact = 0.048/min). In contrast, NNC55-0396 (IC₅₀ = 29 ± 1.2 nM, K_i = 2.8 ± 0.3 nM) and Ro40-5966 (IC₅₀ = 46 ± 11 nM, K_i = 4.5 ± 0.02 nM) have a 3- to 4-fold greater inhibitory activity toward recombinant CYP2D6 than mibefradil (IC₅₀ = 129 ± 21 nM, K_i = 12.7 ± 0.9 nM). Our results suggest that NNC55–0396 could be a more favorable T-type Ca²⁺ antagonist than its parent compound, mibefradil, which was withdrawn from the market because of strong inhibition of CYP3A4.

View larger version (27K): [in this window] [in a new window]   FIG. 1. Chemical structures of mibefradil, NNC55-0396, and the hydrolyzed metabolite of mibefradil, Ro 40-5966.

Mibefradil is metabolized mainly in the liver, producing as many as 30 metabolites (Wiltshire et al., 1997a,b). Metabolism consists of a combination of P450-mediated oxidation, hydrolysis of the ester side chain by CYP3A4 and esterases, and conjugation with glucuronic acid by UDP glucuronosyltransferases (UGTs) (Wiltshire et al., 1997b; Ernst and Kelly, 1998). One of the major hydrolyzed metabolites, Ro 40-5966 (Fig. 1), was shown to strongly bind to L-type Ca²⁺ channels (Wu et al., 2000). Thus, L-type activity is a nonspecific feature of mibefradil administration (Li et al., 2005) and may account for other adverse effects associated with mibefradil. Recently, several analogs of mibefradil have been synthesized and tested for effects against T-type and L-type Ca²⁺ channels (Huang et al., 2004; Li et al., 2005). These analogs were designed to achieve more selectivity toward T-type Ca²⁺ channels. One of these is NNC55-0396, which has been shown to be equipotent as mibefradil in antagonizing the T-type Ca²⁺ channel while exhibiting no L-type Ca²⁺ channel inhibition. NNC55-0396 was developed to be resistant to hydrolysis by substituting the methoxyacetyl side chain of mibefradil with cyclopropanecarboxylate (Fig. 1) (Huang et al., 2004; Li et al., 2005). This compound is not able to generate the hydrolyzed L-type Ca²⁺ channel blocker metabolite, Ro 40-5966, thus rendering NNC55-0396 selective to T-type Ca²⁺ channels (Huang et al., 2004; Li et al., 2005). Such a selective T-type Ca²⁺ channel antagonist, if found to possess a favorable safety profile, would represent a desirable therapeutic for chronic hypertension (Li et al., 2005), a disorder characterized by T-type Ca²⁺ channel up-regulation in animals (Nuss and Houser, 1993).

A critical safety issue is whether NNC55-0396 has a more favorable P450 inhibition profile than mibefradil because such information would predict its potential for drug interactions. After preliminary observations indicated differences in behavioral drug interactions involving mibefradil and NNC55-0396 in mice (our unpublished data), we conjectured that NNC55-0396 may have, despite similarities in structure, a more benign P450 inhibition profile than mibefradil. In this article, we compared NNC55-0396's P450 inhibition profile with that of mibefradil and with that of the latter's hydrolyzed metabolite, Ro 40-5966, using both recombinant human P450s and human liver microsomes. These in vitro studies suggest that NNC55-0396 may be a more beneficial therapeutic agent for T-type Ca²⁺ channel antagonist.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Chemical and Enzymes. Bacterial membranes containing P450s and NAPDH-P450-reductase (CPR), and human liver microsomes were obtained from BD Gentest (Franklin Lakes, NJ). Crude bacterial lysate containing the recombinant human CYP3A4 + CPR and P450 reaction buffer mixtures containing the NADP(+)/H regeneration enzymes were obtained from Bio-Catalytics, Inc. (Pasadena, CA). Porcine liver esterase was obtained from Sigma-Aldrich (St. Louis, MO). The fluorescent substrates 3-[2-N,N-diethyl-N-methylamino]-7-methoxy-4-methylcoumarin (AMMC), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-methoxy-4-trifluoromethylcoumarin (MFC), and 7-hydroxy-4-trifluoromethylcoumarin (HFC) were purchased from BD Gentest. Testosterone, 6β-hydroxytestosterone, harmaline, harmalol, mibefradil, and NNC55-0396 were obtained from Sigma-Aldrich. All the high-performance liquid chromatography (HPLC) solvents (HPLC grade) were obtained from Sigma-Aldrich.

K_m Determination for Probe Substrates. To determine the K_m of BFC and AMMC for recombinant CYP3A4 and CYP2D6, respectively, seven different concentrations of substrates were incubated in 200-µl reactions with 30 nM recombinant P450 + CPR and 1x reaction buffer. The reactions were terminated after 10 min at 37°C by the addition of 200 µl of ice-cold acetonitrile. A similar procedure was used to determine the K_m of testosterone and harmaline for human liver microsomes with the final concentration of microsomes being 0.13 mg/ml and time of incubation being 5 min at 37°C. All the samples were analyzed in duplicate. The reactions were frozen in dry-ice methanol for 5 min to precipitate proteins, followed by centrifugation at 13,000g for 15 min to remove proteins. The supernatants were analyzed by HPLC with diode array and fluorescence detectors. The K_m of each substrate was then calculated with Prism software (GraphPad Software Inc., San Diego, CA) using nonlinear regression with the Michaelis-Menten equation.

Incubations of Bacterially Recombinant Human P450s with Substrates and Inhibitors. Assays were conducted in 1.5-ml Eppendorf tubes in duplicate. Two hundred-microliter reactions contained 1x reaction buffer mixture (pH 7.5, NADPH/NADP+ regenerating enzymes), 30 nM recombinant P450 + CPR, 100 µM BFC or MFC, or 10 µM AMMC, and various concentrations of inhibitors. One hundred-micromolar MFC was used as a probe substrate for CYP1A2, CYP2C9, CYP2C19, CYP2C8, and CYP2E1; 100 µM BFC was used for CYP3A4, and 10 µM AMMC was used for CYP2D6. The substrates and the inhibitors (mibefradil, Ro 40-5966, and NNC55-0396) were all dissolved in acetonitrile. One hundred five microliters of an enzyme buffer (EB) was prepared first that contained the 2x reaction buffer and 60 nM P450 enzymes. The EB was prewarmed for 3 min at 37°C. The reaction was initiated by the addition of 95 µl of substrate and inhibitor mixture containing substrate and the inhibitor or vehicle (acetonitrile). One hundred nanomolar (low concentration) and 10 µM (high concentration) inhibitors were used in the preliminary inhibition studies. Ten micromolar inhibitors and eight successive 3:1 dilution concentrations were used in IC₅₀ value determinations. The reactions were terminated after 20 min at 37°C by the addition of 200 µl of ice-cold acetonitrile. The reactions were frozen in dry-ice methanol for 5 min to precipitate proteins, followed by centrifugation at 13,000g for 15 min to remove proteins. The supernatants were analyzed by HPLC with diode array and fluorescence detectors.

Incubations of Human Liver Microsomes with Testosterone, Harmaline, and Inhibitors. Incubations were conducted in duplicate with a 200-µl volume in Eppendorf tubes. An EB was prepared that contained 0.13 mg/ml human liver microsomes and 2x reaction mixture buffer (pH 7.5, NADPH and NADP+/H regenerating enzymes and proprietary stabilizers, purchased from BioCatalytics, Inc.). One hundred five microliters of EB was prewarmed for 3 min at 37°C. The reaction was initiated by adding 95 µl of substrate and inhibitor mixture containing 200 µM testosterone or 20 µM harmaline and various concentrations of inhibitors. Ten micromolar inhibitors and eight successive 3:1 dilution concentrations were used in IC₅₀ value determinations. Acetonitrile was used as vehicle. The reactions were stopped after 5-min incubation at 37°C with 200 µl of acetonitrile (2% acetic acid). The samples were frozen in dry-ice methanol for 5 min, followed by centrifugation at 13,000g for 15 min to remove proteins. The supernatant was analyzed by HPLC with diode array and fluorescence detectors.

Hydrolysis of Mibefradil and NNC55-0396 Using Pig Liver Esterase and Alkaline Hydrolysis. Forty micromolar NNC55-0396 or mibefradil was incubated with 27 unit/ml pig liver esterase for 1 h at 37°C. The reactions were stopped with 1x volume acetonitrile, and the incubation mixtures were centrifuged at 13,000g for 20 min. Supernatants were analyzed by HPLC. Ro 40-5966 was synthesized using alkaline hydrolysis as described previously with some modifications (Wu et al., 2000) as follows: 500 µl of 4 mM mibefradil in acetonitrile was added to 125 µl of 10 N NaOH; the mixture was incubated for 12 min in a boiling water bath and then neutralized with 125 µl of 5 M hydrochloric acid. Because of the evaporation of acetonitrile, the volume was adjusted with acetonitrile to the starting volume of 500 µl. Complete hydrolysis was checked by HPLC. All the samples were analyzed with a C₁₈ reverse-phase column (150 x 4.6 mm, 5 µm, Vydac; Grace, Deerfield, IL). Mibefradil, NNC55-0396, and Ro 40-5966 were monitored with fluorescence at 270/300 nm (excitation/emission ) and with UV absorbance at 275-nm wavelength. The HPLC condition was set at 70% B isocratic for 30 min (solvent A: H₂O, 0.1% acetic acid, and 5 mM potassium phosphate, pH 7.5; solvent B: acetonitrile).

Time- and Concentration-Dependent Inhibition of Recombinant CYP3A4 by NNC55-0396 and Mibefradil. Studies on the mechanism-based inhibition of CYP3A4 were performed using the testosterone 6β-hydroxylase assay at a high concentration of testosterone (500 µM) to minimize the possibility of competitive inhibition by the inhibitors. Instead of bacterial membrane containing CYP3A4 + CPR, crude bacterial lysate containing CYP3A4 + CPR was used. The crude lysate was shown not to have more than 15% autoinactivation over the preincubation period in the absence of the inhibitors. All the reactions were carried out at 37°C in duplicate. One hundred nanomolar human recombinant CYP3A4 + CPR was preincubated with NAPDH (1 mM) in the presence of 0, 133, 400, 1200, and 3600 nM NNC55-0396 or 44, 133, and 400 nM mibefradil, in a final volume of 120 µl containing 0.1 M potassium phosphate buffer, pH 7.5. At 0, 4, 8, 12, and 16 min, 20-µl aliquots of the reaction mixture were transferred into 180 µl of secondary reactions containing 500 µM testosterone in the reaction buffer mixture, pH 7.5 (NADPH and NADP+/H regenerating enzymes). CYP3A4 testosterone 6β-hydroxylase activity in the secondary reactions was then determined using HPLC. The kinetics of CYP3A4 inactivation were determined as follows: the initial rate constant for inactivation (K_obs) at each concentration of inhibitor was estimated from the slope of the linear regression line (by Prism software) from the log of CYP3A4 remaining activity versus the preincubation time semilog graph. Kinetic parameters (K_inact and K_I) for the inactivation of CYP3A4 testosterone 6β-hydroxylase activity were then estimated from the reciprocal plot of the rate constant (K_obs) versus the inhibitor concentrations.

Analytical Procedures. All the samples were analyzed using HPLC. The HPLC system consisted of the Shimadzu (Kyoto, Japan) prominence series, including the LC-20 AT prominence LC pump, DGU-20A₅ degasser, CBM-20 prominence communications bus module, SPD-20A prominence UV-visible detector, and RF-10AXL fluorescence detector (Shimadzu). A C₁₈ reversed-phase column (4.6 x 150 mm, 5 µm; Waters, Milford, MA) was used to detect and quantify metabolite products of MFC, BFC, and AMMC. The separation was achieved with 20% B from 0 to 5 min, linearly increased to 90% B from 5 min to 15 min, and was held until 20 min before returning to the starting condition (solvent A: 5 mM potassium phosphate, pH 7.5; solvent B: 100% acetonitrile; flow rate 1 ml/min). HFC, a product of MFC and BFC, and 3-[2-N,N-diethyl-N-methylamino]-7-hydroxy-4-methylcoumarin, a product of AMMC, were monitored by fluorescence detection with the setting at 410/510 nm (excitation/emission ) and 390/460 nm (excitation/emission ), respectively. For samples of testosterone and harmaline, a C₁₈ reversed-phase column (4.6 x 250 mm, 5 µm; DuPont, Wilmington, DE) was used. The separation of testosterone samples was performed using 40% B from 0 to 5 min, increasing to 80% B from 5 min to 12 min, and then holding for another 17 min before returning to the starting condition (solvent A: H₂O, 0.1% trifluoric acid; solvent B: 100% acetonitrile; flow rate 1 ml/min). The testosterone metabolite, 6β-hydroxytestosterone, was monitored at a wavelength of 240 nm and eluted at 5.7 min. For harmaline, solvents were held isocratic at 30% B from 0 to 8 min. The gradient was linear from 30% B to 70% B from 8 min to 12 min and held at 70% until 17 min; before returning to starting conditions (solvent A: H₂O, 0.1% trifluoroacetic acid; solvent B: 100% acetonitrile; flow rate 1 ml/min). The harmaline metabolite, harmalol, was monitored with the fluorescence detector setting at 340/495 nm (excitation/emission ) and eluted at 4.9 min.

Data Analysis. The P450 activities with and without inhibitors were measured by the area of products from the HPLC chromatograms. The activities of P450s in the presence of the inhibitors are addressed as the percentage activity of uninhibited P450s (area of product of the inhibited samples divided by the uninhibited samples times 100%). The IC₅₀ values were determined by Prism software using the nonlinear regression mode with one site competition. The equilibrium dissociation constant of inhibitor, K_i, was calculated by Prism software using the IC₅₀ values, the given concentration and the K_m of the respective probe substrate, and the equation, K_i = (IC₅₀)/[1 + (substrate)/K_m] (Linden, 1982). Calculations of the K_m for probe substrates and the kinetics of enzyme inactivations were described previously above. The t test was used for statistical analysis (Prism software).

	Results

Top Abstract Materials and Methods Results Discussion References

 
Comparison of NNC55-0396's P450 Inhibition Profile with That of Mibefradil. Seven major recombinant human P450s— CYP3A4, CYP1A2, CYP2E1, CYP2D6, CYP2C8, CYP2C19, and CYP2C9 —were chosen for inhibition studies with mibefradil and NNC55-0396. It has been shown that these P450s participate in the metabolism of approximately 80% of therapeutic drugs (Wienkers and Heath, 2005). To obtain a preliminary look at the P450 inhibitory profiles for mibefradil and NNC55-0396, two concentrations of the inhibitors were chosen, 100 nM and 10 µM. These two concentrations represent the low and the high concentrations and cover the range of therapeutic plasma concentrations of the inhibitors because it has been reported that the human therapeutic plasma concentration of mibefradil ranges from 300 to 1000 ng/ml after doses of 50 to 100 mg/day, which correspond to 0.5 to 1.8 µM mibefradil (Wiltshire et al., 1997a; Welker and Banken, 1998). At 100 nM, mibefradil exhibited more than a 2-fold greater inhibition than NNC55-0396 for CYP3A4 (63 and 27%, respectively, p < 0.001) (Fig. 2F). At 10 µM, both mibefradil and NNC55-0396 inhibited more than 90% of CYP3A4 activity (Fig. 2F). Mibefradil and NNC55-0396 had opposite inhibitory effects to those above for CYP2D6. At 100 nM, NNC55-0396 exhibited more than 2-fold greater inhibition of CYP2D6 compared with mibefradil (55 and 23%, respectively, p < 0.001) (Fig. 2G). At 10 µM, both compounds inhibited CYP2D6 > 95% (Fig. 2G). Our mibefradil data are in agreement with previous reports showing that mibefradil strongly inhibits CYP3A4 and CYP2D6 (Ernst and Kelly, 1998; Prueksaritanont et al., 1999; Stresser et al., 2000). Mibefradil at 100 nM slightly inhibited CYP2C9 (11%, p < 0.05) (Fig. 2C), whereas NNC55-0396 at 100 nM failed to do so (Fig. 2C). Neither CYP2C8 nor CYP2C19 was inhibited by 100 nM mibefradil or NNC55-0396, and 10 µM concentrations of these compounds inhibited CYP2C9, CYP2C8, and CYP2C19 considerably less than they inhibited CYP3A4 and CYP2D6 (Fig. 2, C–E). CYP2E1 and CYP1A2 were not inhibited by either compound, even at 10 µM (Fig. 2, A and B).

View larger version (42K): [in this window] [in a new window]   FIG. 2. Inhibition profile of the activities of various human P450s by 100 nM and 10 µM mibefradil (Mib) or NNC55-0396 (NNC). The inhibition activities of CYP1A2 (A), CYP2E1 (B), CYP2C9 (C), CYP2C19 (D), CYP2C8 (E), CYP3A4 (F), and CYP2D6 (G) are expressed relative to the activities of the no inhibitor control (ACN) as the percentage of the inhibited activity over the uninhibited one. Thus, the percent of inhibition is calculated as 100% minus the percent listed on the graph. Data are represented as the mean ± S.D. of duplicate determinations. * and ***, p < 0.05 and p < 0.001, respectively, for comparison between control (ACN) and inhibitor added samples by an unpaired t test.

IC₅₀ and K_i Values of Mibefradil and NNC55-0396 for Recombinant CYP3A4 and CYP2D6. Our preliminary look at the P450 inhibitory profiles for mibefradil and NNC55-0396 therefore showed that of the above P450s, only recombinant CYP3A4 and CYP2D6 exhibited marked inhibition by both compounds at low concentrations. Therefore, we went on to compare the inhibitory effects of the above compounds on CYP3A4 and CYP2D6 by estimating their IC₅₀ and K_i values. We determined the IC₅₀ values of mibefradil and NNC55-0396 using eight inhibitor concentrations generated by serial 1:3 dilutions from 10 µM. Although the IC₅₀ value expresses the concentration of the inhibitor that competes for half the specific substrate binding sites, it does not quantify the affinity of the inhibitor for the enzyme. K_i, the equilibrium dissociation constant, is a measure of this last parameter. It is the concentration of the inhibitor that will bind to half the binding sites at equilibrium and is calculated based on the IC₅₀ values of inhibitor, the substrate's K_m, and the given substrate concentration (Linden, 1982) The K_ms of BFC and AMMC, the substrates for CYP3A4 and CYP2D6, respectively, were determined to be 240 and 1.08 µM, respectively. For CYP3A4 inhibition, the IC₅₀ and K_i values of mibefradil were 33 ± 3 and 23 ± 0.5 nM, whereas the IC₅₀ and K_i values of NNC55-0396 were 300 ± 30 and 210 ± 6 nM (Fig. 3A), showing that NNC55-0396 is nine times less inhibitory than mibefradil toward recombinant human CYP3A4 (p < 0.001) (Fig. 3A). Our mibefradil IC₅₀ value for recombinant CYP3A4 is similar to that reported by Stresser et al. (2000). For CYP2D6 inhibition, mibefradil had IC₅₀ and K_i values of 129 ± 21 and 12.7 ± 0.9 nM, whereas NNC55-0396 had IC₅₀ and K_i values of 29 ± 1.2 and 2.8 ± 0.3 nM, representing a 4-fold greater inhibition efficacy for NNC55-0936 compared with mibefradil (p < 0.005) (Fig. 3B).

View larger version (23K): [in this window] [in a new window]   FIG. 3. Comparison of mibefradil and NNC55-0936 inhibition of CYP3A4 and CYP2D6. A, the IC50 and Ki determination of mibefradil and NNC55 for BFC debenzylation by CYP3A4. B, the IC50 and Ki determination of mibefradil and NNC55-0396 for AMMC N-demethylation by CYP2D6. Data are represented as the averages ± S.D. of duplicate determinations. **, p < 0.005 comparing the mibefradil and NNC55-0396 samples by a paired t test.

View larger version (26K): [in this window] [in a new window]   FIG. 4. Inhibition profiles for testosterone and harmaline metabolism in human liver microsomes by mibefradil and NNC55-0936. A, IC50 and Ki determination of mibefradil and NNC55-0396 for testosterone metabolism mainly by CYP3A in human liver microsomes. ***, p < 0.001 comparing the mibefradil and NNC55-0396 samples by a paired t test. B, IC50 and Ki determination of mibefradil and NNC55-0396 for harmaline metabolism mainly by CYP2D6 in human liver microsomes. **, p < 0.01 for comparing NNC55-0396 to mibefradil by a paired t test.

Effects of Esterase on Mibefradil and NNC55-0396. Mibefradil is easily hydrolyzed by enzymes after it enters the cell (Wiltshire et al., 1992; Wu et al., 2000). Its hydrolyzed metabolite, Ro 40-5966, has been shown to block L-type Ca²⁺ channels (Wu et al., 2000). NNC55-0396 has more specific inhibitory activity toward T-type Ca²⁺ channels than mibefradil (Huang et al., 2004; Li et al., 2005), most likely because of its resistance to hydrolysis conferred by the replacement of the methoxy acetate chain with cyclopropanecarboxylate. To test whether NNC55-0396 is more resistant to hydrolysis by esterase than mibefradil, both were incubated with pig liver esterase. Pig liver esterases are commonly used for in vitro study because human esterases are not available. Our data show that after 1 h at 37°C, 10% of mibefradil was hydrolyzed by esterase to yield a product peak at 15.5 min that corresponds to the Ro 40-5966 standard (Fig. 5B), whereas no hydrolyzed product was detected in NNC55-0396 sample incubated with esterase (Fig. 5A). Thus, mibefradil is susceptible to hydrolysis by the esterase yielding Ro 40-5966, whereas NNC55-0396 is not. However, whether NNC55-0396 is resistant to hydrolysis in humans needs to be examined.

View larger version (21K): [in this window] [in a new window]   FIG. 5. Hydrolysis of mibefradil but not NNC55-0396 by pig liver esterase. A, HPLC chromatograms of 40 µM NNC55-0396 incubated with pig liver esterase (solid line) and of a standard for Ro 40-5966 (broken line). The 14- and 15.5-min peaks correspond to NNC55-0396 and Ro 40-5966, respectively. B, HPLC chromatograms of 40 µM mibefradil incubated with pig liver esterase (solid line) and of standard Ro 40-5966 (broken line). The 11.5- and 15.5-min peaks correspond to mibefradil and Ro 40-5966, respectively. Open arrow indicates the presence of Ro 40-5966 at 15.5 min generated by hydrolysis in the mibefradil sample.

P450 Inhibition Profile of Mibefradil's Hydrolyzed Metabolite, Ro 40-5966, in Comparison with Mibefradil and NNC55-0396. According to Wiltshire et al. (1992, 1997a), 20 to 32% of mibefradil is converted to Ro 40-5966 after clinical administration. Although it has been shown here and by others that mibefradil inhibits several P450s, it has not previously been investigated whether Ro 40-5966 can also inhibit P450s. Therefore, we tested Ro 40-5966's inhibition toward recombinant CYP2D6, CYP3A4, CYP2C9, CYP1A2, CYP2C19, and CYP2C8 (Fig. 6, A–F). As with mibefradil and NNC55-0396, only recombinant CYP3A4 and CYP2D6 showed strong inhibition by Ro 40-5966 (Fig. 6, A and B). Our results show that Ro 40-5966 has IC₅₀ and K_i values of 30 ± 7.8 and 21 ± 2.8 nM for CYP3A4, which are comparable with mibefradil's values of 33 ± 3 and 23 ± 0.5 nM (Figs. 3A and 6B). These IC₅₀ and K_i values indicate that like mibefradil, Ro 40-5966 is 9 to 10 times more inhibitory than NNC55-0396 toward recombinant CYP3A4, which has IC₅₀ and K_i values of 300 ± 30 and 210 ± 6 nM (Fig. 3A). For recombinant CYP2D6, Ro 40-5966 was determined to have IC₅₀ and K_i values of 46 ± 11 and 4.5 ± 0.02 nM (Fig. 6A), which are comparable with the values for NNC55-0396 (IC₅₀ = 29 ± 1.2 and K_i = 2.8 ± 0.3 nM) (Fig. 3B). Comparison of the inhibition values of Ro 40-5966 with that of mibefradil (IC₅₀ = 129 ± 21 and K_i = 12.7 ± 0.9 nM) (Fig. 3B) indicates a 3-fold greater inhibition efficacy of Ro 40-5966 toward CYP2D6 (p < 0.05) (Figs. 3B and 6A). Inhibition of CYP2C19 and CYP1A2 by Ro 40-5966 was observed only at the supraoptimal concentration of 10 µM(p < 0.001) (Fig. 6, D and E). The IC₅₀ for CYP2C9 was estimated to be 823 ± 390 nM (Fig. 6C), whereas there was no significant inhibition of CYP2C8 even at 10 µM concentration (Fig. 6F).

View larger version (32K): [in this window] [in a new window]   FIG. 6. Inhibition profiles of the activities of various human P450s by Ro 40-5966. The IC50 and Ki determinations of Ro 40-5966 for recombinant CYP2D6 (A) and CYP3A4 (B), and the IC50 determinations for CYP2C9 (C) and CYP1A2 (D). The relative activities of 100 nM and 10 µM Ro 40-5966 samples to a control (ACN) catalyzed by recombinant CYP2C19 (E) and CYP2C8 (F). IC50 determinations for CYP2C19 and CYP2C8 were not necessary because they were not strongly inhibited by Ro 40-5966 even at 10 µM. Data are represented as the mean ± S.D. of duplicate determinations. *, p < 0.05 comparing control (ACN) and Ro 40-5966 samples by an unpaired t test.

Inhibition Mechanism of Mibefradil and NNC55-0396 toward Recombinant CYP3A4. Mibefradil has been shown to be a powerful mechanism-based inhibitor of CYP3A4 (Prueksaritanont et al., 1999). Our preliminary data indicated that NNC55-0396 also exhibited time-dependent inactivation of CYP3A4. To further investigate the inhibition mechanism of NNC55-0396 and to compare it with that of mibefradil, mechanism-based inhibition assays were performed using recombinant human CYP3A4-catalyzed testosterone 6β-hydroxylase activity. Crude lysate containing CYP3A4 was used instead of a membrane fraction containing the enzyme because the latter was shown to have a 50% decrease in activity during the period of incubation even in the absence of inhibitor, whereas the former showed no more than 15% autoinactivation. The kinetic parameters, such as the concentration required for half-maximal inactivation (K_I) and the rate constant of maximal inactivation at saturation (K_inact), were determined. These numbers were used to compare the inactivation efficiency of mibefradil and NNC55-0396 toward the CYP3A4 enzyme. Preincubation of recombinant CYP3A4 with various concentrations of mibefradil and NNC55-0396 in the presence of NADPH resulted in a time- and concentration-dependent loss of testosterone 6β-hydroxylase activity. However, NNC55-0396 significantly caused time-dependent inactivation of testosterone 6β-hydroxylase only at the high concentrations 1.2 and 3.6 µM compared with the control (p < 0.05) (Fig. 7C). The K_I and K_inact of NNC55-0396 for CYP3A4 were estimated to be 3.87 µM and 0.061/min, respectively (Fig. 7D).

View larger version (27K): [in this window] [in a new window]   FIG. 7. Mechanism-based inactivation of recombinant human CYP3A4 by mibefradil and NNC55-0396. Time- and concentration-dependent loss of recombinant CYP3A4 testosterone 6β-hydroxylase activity with mibefradil and NAPDH (A) or NNC55-0396 and NAPDH (C). The double reciprocal plot of the rates of inactivation as a function of the mibefradil (B) and NNC55-0396 (D) concentration. The values for 1/Kobs (/min) were calculated from the slopes of inactivation experiments by mibefradil or NNC55-0396 in A or C, respectively. All the slopes were normalized to the slope of no inhibitor experiment. The KI and Kinact values are estimated by 1 divided by the x- and y-intercepts, respectively. * and **, p < 0.05 and 0.01, respectively, comparing with control (0 nM) samples by an unpaired t test.

In contrast, mibefradil significantly caused time-dependent loss of testosterone 6β-hydroxylase activity even at 44 nM, the lowest concentration tested (p < 0.01) (Fig. 7A). The estimated K_I and K_inact of mibefradil were 83 nM and 0.048/min, respectively (Fig. 7B). Therefore, the K_I of mibefradil is 47 times lower than that of NNC55-0396. From the kinetics values, the inactivation efficiency [E_inact = K_inact/(K_I + I)] can be estimated (Zhou et al., 2005). E_inact of mibefradil is at least 3.3-fold higher than that of NNC55-0396 for inactivating CYP3A4 testosterone 6β-hydroxylase, when the inhibitor concentrations are at 1 µM or less. The lower the inhibitors' concentrations, the greater the difference in inactivation efficiency between mibefradil and NNC55-0396.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Mibefradil, a potent T-type Ca²⁺ channel inhibitor, was marketed clinically for cardiac indications but was withdrawn after serious drug-drug interactions emerged, particularly because of CYP3A4 inhibition and inactivation. It also has the disadvantage of L-type Ca²⁺ channel antagonism contributed by its hydrolyzed metabolite, Ro 40-5966. Recently, a mibefradil derivative, NNC55-0396, designed to be hydrolysis-resistant, was shown to be a selective T-type Ca²⁺ channel inhibitor without L-type Ca²⁺ channel efficacy (Li et al., 2005). Whether NNC55-0396 will deliver a clinical benefit with minimized drug-drug interactions is not known. However, potential adverse effects can often be predicted. In the preclinical drug discovery and development phase, studies of P450 enzyme inhibition and inactivation have become one of the major approaches for the in vitro assessment of the risk associated with new molecular entities as precipitants of drug-drug interactions (Venkatakrishnan et al., 2007). Thus, this report is the first in vitro study of NNC55-0396's effects on human P450s in which its effects are also being compared with mibefradil and its hydrolyzed metabolite, Ro 40-5966. The study will provide crucial information about the possible risk associated with NNC55-0396.

Using seven major recombinant human P450s and human liver microsomes, and HPLC as a detection and analytical method, we showed that compared with mibefradil, NNC55-0396 has a significantly less inhibitory profile for the CYP3A4 activity of recombinant CYP3A4, as well as CYP3A4-dependent activity in human liver microsomes. The IC₅₀ and K_i of NNC55-0396 are both 9 to 10 times higher than those of mibefradil for recombinant CYP3A4, suggesting that the former compound is 9 to 10 times less inhibitory than the latter. The differences in these values are more dramatic when inhibition of testosterone 6β-hydroxylase activity of CYP3A was examined in human liver microsomes. The IC₅₀ and K_i of NNC55-0396 are 19-fold higher than that of mibefradil. The higher IC₅₀ and K_i values observed for CYP3A4 in human liver microsomes compared with the values for recombinant CYP3A4 may result from the presence of other microsomal proteins that bind to the inhibitors, or to the presence of other enzymes that can metabolize the inhibitors, thus making them less available to inhibit the targeted enzyme (Wiltshire et al., 1997a). Moreover, the difference could have been contributed by different substrates being used.

Previous evidence suggested that mibefradil metabolites also inhibit CYP3A4 (Prueksaritanont et al., 1999; Ma et al., 2000), but the degree of inhibition has not previously been investigated. Mibefradil is hydrolyzed by esterase and CYP3A4 to generate a hydroxyl mibefradil, Ro 40-5966 (Wiltshire et al., 1997a), one of many mibefradil metabolites shown to contribute to the L-type Ca²⁺ channel nonspecific inhibition of mibefradil (Wu et al., 2000). Our results show that Ro 40-5966 inhibits CYP3A4 with an efficacy comparable with mibefradil and thus is 10 times more inhibitory than NNC55-0396. This result indicates that the Ro 40-5966 metabolite may also contribute to mibefradil's drug interactions.

When using a time- and concentration-dependent inhibition assay, we found that NNC55-0396 also caused time-dependent inactivation of CYP3A4 but was less potent in this regard than mibefradil. The concentration of NNC55-0396 required for half-maximal inactivation (K_I) of CYP3A4 is 3.4 µM, which is 47-fold higher than that of mibefradil. Its t_1/2inact (0.693/K_inact) is just slightly shorter (11.3 min) than that of mibefradil (14.4 min). K_I values can be used to classify inhibitory potency of compounds (Zhou et al., 2005). The K_I value of NNC55-0396 is comparable with the K_I values of verapamil (1.7 µM) and diltiazem (2.0 µM), which are the Ca²⁺ channel antagonists being used as antihypertensive drugs and are currently available on the market (Zhou et al., 2005). In addition, verapamil and diltiazem even have shorter t_1/2inact (7.70 and 6.30 min, respectively) (Zhou et al., 2005) than that of NNC55-0396.

CYP3A4 is responsible for metabolizing 50 to 60% of all the therapeutic drugs that are metabolized by P450s in humans (Thummel et al., 1996). Drugs that inhibit CYP3A4 such as ketoconazole, cisapride, ritonavir, and nefazodone have been found to cause deleterious side effects when coadministered with other drugs. Therefore, many drugs that strongly inhibit CYP3A4 such as mibefradil have been withdrawn from the market (SoRelle, 1998; Bohets et al., 2000; Watanabe et al., 2007; http://www.fda.gov/medwatch/SAFETY/1997/posico.htm). Mibefradil was shown to strongly inhibit CYP3A4 via mechanism-based inactivation at its relevant therapeutic concentration. Such inhibition is highly potent because it irreversibly reduces the amount of the enzyme available, so that restoration of activity requires the synthesis of new enzyme. The pharmacokinetics of NNC55-0396 need to be determined to get an accurate assessment of its clinical drug-drug interaction outcomes. However, if the pharmacokinetics of NNC55-0396 are the same as mibefradil, then NNC55-0396 would likely be a lesser or even nonpotent mechanism-based inhibitor of CYP3A4 in vivo. Given the total C_max of mibefradil of around 0.5 to 1.8 µM (Wiltshire et al., 1997a; Welker and Banken, 1998) and the fact that more than 90% of mibefradil is protein-bound, the available plasma concentration of NNC55-0396 will be much below its apparent K_i (3.9 µM), and the C_max/K_i ratio of NNC55-0396 would be less than 1 (based on the K_i derived from human liver microsomes). This ratio indicates that drug-drug interaction is unlikely, but possible, because according to the current Food and Drug Administration guidelines for predicting the likelihood of clinically relevant drug-drug interaction if C_max/K_i > 1, a drug interaction is likely, if C_max/K_i > 0.1, a drug interaction is possible, and if C_max/K_i < 0.1, a drug interaction is unlikely. However, it is also possible that the NNC55-0396's C_max will be higher in clinical settings. If this is the case, then the C_max/K_i ratio may be higher than 1, and drug-drug interaction is likely.

CYP2D6 has been reported to be inhibited by mibefradil, but the IC₅₀ and K_i values have not previously been determined. We are the first to report mibefradil's IC₅₀ and K_i values for CYP2D6 and to show that Ro 40-5966 strongly inhibits CYP2D6 with relatively lower IC₅₀ and K_i than its parent compound. This could have also contributed to the complexity of mibefradil's toxicity. Our results also show that NNC55-0396 inhibits CYP2D6 with relatively low IC₅₀ and K_i values with both recombinant CYP2D6 and human liver microsomes. This strong inhibition of CYP2D6 could be a concern because CYP2D6, although playing a less important role than CYP3A4 in drug metabolism, is the second most significant P450 in this regard because it metabolizes 20 to 25% of clinically used drugs (Ingelman-Sundberg, 2004). However, many strong inhibitors of CYP2D6 with low IC₅₀ values, such as terbinafine, dextromethorphan, quinidine, and propranolol, are currently on the market.

Although mibefradil, NNC55-0396, and Ro 40-5966 also inhibit CYP2C9, CYP2C8, and CYP2C19, they do so only at high concentrations (10 µM), indicating that relative high dosages of these drugs would need to be taken to reach sufficiently high plasma levels to inhibit these enzymes. In addition, CYP2C9, CYP2C8, and CYP2C19 have a less important role clinically than CYP3A4 in drug metabolism (Ingelman-Sundberg, 2004). However, they are not irrelevant in drug-drug interactions.

Clinically, T-type Ca²⁺ channels have represented important therapeutic targets in various types of diseases from cardiovascular diseases, diabetes, and neurological diseases to cancer (Li et al., 2005; Tanaka and Shigenobu, 2005; Panner and Wurster, 2006). Besides their strong association with cardiovascular disease, T-type Ca²⁺ channels are associated with cancer cell proliferation, and inhibiting T-type Ca²⁺ channels protects from delayed ischemia-induced damage (Nikonenko et al., 2005). T-type Ca²⁺ channels are also implicated in the pathogenesis of epilepsy and neuropathic pain (Tanaka and Shigenobu, 2005). Thus far, highly selective T-type Ca²⁺ channel antagonists have not been clinically available. Several candidate drugs that potently inhibit T-type Ca²⁺ channels unfortunately, like mibefradil, also strongly inhibit L-type Ca²⁺ channels. Interestingly, a methoxyacetyl group of mibefradil seems to play not only an important role in selectivity toward the Ca²⁺ channels but also in P450 inhibition. We and others (Huang et al., 2004; Li et al., 2005) found changes in inhibition specificities when this ester group is modified. Thus, it is probable that additional nonhydrolyzable analogs of mibefradil could be designed that exert less inhibition of CYP3A4 and CYP2D6 but still retain the same potency for T-type Ca²⁺ channel antagonism.

In summary, our data suggest that NNC55-0396 is a more favorable T-type Ca²⁺ channel antagonist than its parental compound, mibefradil, for the following reasons. 1) NNC55-0396 is a selective T-type Ca²⁺ channel blocker without L-type Ca²⁺ channel efficacy (Li et al., 2005). 2) It has a considerably weaker inhibitory profile for CYP3A4 than mibefradil. Such inhibition of CYP3A4 was an important problem that contributed to mibefradil's withdrawal from the market. 3) Unlike mibefradil, NNC55-0396 is not hydrolyzed by esterase to form Ro 40-5966, itself a very potent CYP3A4 and L-type Ca²⁺ antagonist (Wu et al., 2000). However, freedom from CYP3A4-based interactions will also depend on the pharmacokinetic properties of NNC55-0396. Predicting drug-drug interaction is even more challenging when it involves mechanism-based inactivation of enzyme because the clinical outcomes depend on a number of factors, including the pharmacokinetic effects (K_i, K_inact, and partition ratio), and the zero-order synthesis rate of new or replacement enzyme (Zhou et al., 2005). Nevertheless, our findings are highly suggestive for a weaker interaction CYP3A4 profile for NNC55-0396. More work is needed, however, to establish whether its differences from mibefradil may be clinically meaningful.

	Acknowledgments

 
We thank Dr. Curt Eckhert for allowing us to use his HPLC equipment.

	Footnotes

 
This research is supported by National Institute of Environmental Health Sciences Grant RO1ES015384 to Oliver Hankinson, by a fellowship to Peter Bui from the University of California Toxic Substances Research and Teaching Program, by the Department of Veterans Affairs, and by the Ralph M. Parsons Foundation.

Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

doi:10.1124/dmd.107.020115.

ABBREVIATIONS: P450, cytochrome P450; UGT, UDP glucuronosyltransferase; CPR, NAPDH-P450-reductase; AMMC, 3-[2-N,N-diethyl-N-methylamino]-7-methoxy-4-methylcoumarin; BFC, 7-benzyloxy-4-trifluoromethylcoumarin; MFC, 7-methoxy-4-trifluoromethylcoumarin; HFC, 7-hydroxy-4-trifluoromethylcoumarin; HPLC, high-performance liquid chromatography; EB, enzyme buffer.

Address correspondence to: Oliver Hankinson, Departmental of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, 650 Charles Young Drive, Los Angeles, CA 90095. E-mail: ohank{at}mednet.ucla.edu

	References

Top Abstract Materials and Methods Results Discussion References

 


Armstrong CM and Matteson DR (1985) Two distinct populations of calcium channels in a clonal line of pituitary cells. Science 227: 65-67.[Abstract/Free Full Text]

Bohets H, Lavrijsen K, Hendrickx J, van Houdt J, van Genechten V, Verboven P, Meuldermans W, and Heykants J (2000) Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol 129: 1655-1667.[CrossRef][Medline]

Clozel JP, Banken L, and Osterrieder W (1989) Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 14: 713-721.[Medline]

Clozel JP, Veniant M, and Osterrieder W (1990) The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 4: 731-736.[CrossRef][Medline]

Ernst ME and Kelly MW (1998) Mibefradil, a pharmacologically distinct calcium antagonist. Pharmacotherapy 18: 463-485.[Medline]

Gillam EM, Baba T, Kim BR, Ohmori S, and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305: 123-131.[CrossRef][Medline]

Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, Zhang M, Ragsdale DS, and Li M (2004) NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluo ro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther 309: 193-199.[Abstract/Free Full Text]

Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25: 193-200.[CrossRef][Medline]

Li M, Hansen JB, Huang L, Keyser BM, and Taylor JT (2005) Towards selective antagonists of T-type calcium channels: design, characterization and potential applications of NNC 55-0396. Cardiovasc Drug Rev 23: 173-196.[Medline]

Linden J (1982) Calculating the dissociation constant of an unlabeled compound from the concentration required to displace radiolabel binding by 50%. J Cyclic Nucleotide Res 8: 163-172.[Medline]

Ma B, Prueksaritanont T, and Lin JH (2000) Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28: 125-130.[Abstract/Free Full Text]

Massie BM (1997) Mibefradil: a selective T-type calcium antagonist. Am J Cardiol 80: 23I-32I.[CrossRef][Medline]

Nikonenko I, Bancila M, Bloc A, Muller D, and Bijlenga P (2005) Inhibition of T-type calcium channels protects neurons from delayed ischemia-induced damage. Mol Pharmacol 68: 84-89.[Abstract/Free Full Text]

Nuss HB and Houser SR (1993) T-type Ca2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 73: 777-782.[Abstract/Free Full Text]

Oparil S and Calhoun DA (1991) The calcium antagonists in the 1990s. An overview. Am J Hypertens 4: 396S-405S.[Medline]

Panner A and Wurster RD (2006) T-type calcium channels and tumor proliferation. Cell Calcium 40: 253-259.[CrossRef][Medline]

Perez-Reyes E, Cribbs LL, Daud A, Lacerda AE, Barclay J, Williamson MP, Fox M, Rees M, and Lee JH (1998) Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature 391: 896-900.[CrossRef][Medline]

Portegies MC, Schmitt R, Kraaij CJ, Braat SH, Gassner A, Hagemeijer F, Pozenel H, Prager G, Viersma JW, van der Wall EE, et al. (1991) Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 18: 746-751.[Medline]

Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, and Baillie TA (1999) Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br J Clin Pharmacol 47: 291-298.[CrossRef][Medline]

Rogers R and Prpic R (1998) Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy. Med J Aust 169: 425-427.[Medline]

Rutledge A and Triggle DJ (1995) The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue. Eur J Pharmacol 280: 155-158.[CrossRef][Medline]

Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, and Haefeli WE (1998) Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 351: 1929-1930.[CrossRef][Medline]

SoRelle R (1998) Withdrawal of Posicor from market. Circulation 98: 831-832.[Free Full Text]

Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28: 1440-1448.[Medline]

Tanaka H and Shigenobu K (2005) Pathophysiological significance of T-type Ca2+ channels: T-type Ca2+ channels and drug development. J Pharmacol Sci 99: 214-220.[CrossRef][Medline]

Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59: 491-502.[CrossRef][Medline]

Triggle DJ (1991) Sites, mechanisms of action, and differentiation of calcium channel antagonists. Am J Hypertens 4: 422S-429S.[Medline]

Varis T, Backman JT, Kivisto KT, and Neuvonen PJ (2000) Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 67: 215-221.[CrossRef][Medline]

Venkatakrishnan K, Obach RS, and Rostami-Hodjegan A (2007) Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37: 1225-1256.[CrossRef][Medline]

Wandel C, Kim RB, Guengerich FP, and Wood AJ (2000) Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 28: 895-898.[Abstract/Free Full Text]

Watanabe A, Nakamura K, Okudaira N, Okazaki O, and Sudo K (2007) Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos 35: 1232-1238.[Abstract/Free Full Text]

Welker HA and Banken L (1998) Mibefradil pharmacokinetic and pharmacodynamic population analysis. Int J Clin Pharmacol Res 18: 63-71.[Medline]

Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4: 825-833.[CrossRef][Medline]

Wiltshire HR, Harris SR, Prior KJ, Kozlowski UM, and Worth E (1992) Metabolism of calcium antagonist Ro 40-5967: a case history of the use of diode-array u.v. spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway. Xenobiotica 22: 837-857.[Medline]

Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Harris SR, Worth E, and Welker HA (1997a) Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica 27: 557-571.[CrossRef][Medline]

Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Madigan MJ, and Sharp SR (1997b) Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part II. Metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man. Xenobiotica 27: 539-556.[CrossRef][Medline]

Wu S, Zhang M, Vest PA, Bhattacharjee A, Liu L, and Li M (2000) A mibefradil metabolite is a potent intracellular blocker of L-type Ca(2+) currents in pancreatic beta-cells. J Pharmacol Exp Ther 292: 939-943.[Abstract/Free Full Text]

Yu AM, Idle JR, Krausz KW, Kupfer A, and Gonzalez FJ (2003) Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305: 315-322.[Abstract/Free Full Text]

Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, and McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44: 279-304.[CrossRef][Medline]

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.107.020115v1 36/7/1291    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bui, P. H. Articles by Hankinson, O. Search for Related Content PubMed PubMed Citation Articles by Bui, P. H. Articles by Hankinson, O.